Edgar Stene Prize 2021
Each year at EULAR the Edgar Stene Prize will be rewarded, and in 2021 it will be at the Opening Plenary Session of the forthcoming European Congress of Rheumatology in Paris, France, on 2 June 2021.
Eular invites people with RMDs to write about their personal experiences. This year the topic is:
“How digital solutions benefit my life as a person with an RMD”.
Digitalization was already a hot topic before the pandemic hit the world and since then there is no way around it. It impacts on all areas of our lives and although the virtual world can never replace the human contact it definitely offers some advantages. We would love to hear what you feel about it – do you make use of digital solutions? If yes, how does these look like and how are they of relevance in connection with your RMD? We invite you to reflect broadly here, starting with your personal contacts and relationships during the pandemic, considering the use of e-health applications like self-management apps or wearables to monitor your health, or the use of telemedicine or an electronic prescription for the pharmacy. What is already reality in your country and what would you like to see implemented in the future?
As in the past, national EULAR member organisations of PARE are encouraged to organise national competitions for people with a rheumatic or musculoskeletal disease (minimum 18 years of age). Competitors should be invited to submit an essay not exceeding 2 pages (A4) in their own language to their national EULAR member organisation of PARE. The deadline for the national completion will be set individually by each national organisation. Anyone who would like to submit an essay should get in touch with their respective national EULAR member organisation of PARE for further information.
Each national jury should select and submit the best entry from their country (only one entry) by email to the EULAR Secretariat by 20 January 2021.
news & events
Are you living with diffuse scleroderma?
Would you like to be involved in a clinical study testing a new investigational drug for use in Diffuse Scleroderma?
If so, you may be eligible to take part in the DECODE Scleroderma Study
FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.
We are happy to share with you our latest newsletter. Read about World Scleroderma Day 2021, projects, our next world congress and more.